TOP216 / Valerio Therap - LARVOL DELTA

[VIRTUAL] TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE FOLLOWING FRONTLINE DASATINIB: RESULTS FROM JALSG D-STOP216 (EHA 2021) - "Background Previously reported results from JALSG CML212 (UMIN000007909), a multicenter open-labeled prospective randomized controlled phase 3 study on de novo chronic myeloid leukemia in chronic phase (CML-CP), showed that cumulative achievement rates of MR4.5 (BCR-ABL1 ≤0.0032% on the International Scale [BCR-ABL1IS]) by 18 months were 33.0% (75/227) (95% CI:27.0–39.6%) in the nilotinib arm and 30.8% (70/227) (95% CI: 24.9–37.3%) in the dasatinib (DAS) arm, with no significant difference. After stopping DAS, 59.2% of patients remained in TFR 12 months later. The results suggest that a higher proportion of patients with CML-CP who achieved sustained MR4.5 on frontline DAS will remain progression free without treatment compared with that in previous TFR trials."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR

[VIRTUAL] TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE FOLLOWING FRONTLINE NILOTINIB: RESULTS FROM JALSG N-STOP216 (EHA 2021) - "Background Previously reported results from JALSG CML212 (UMIN000007909), a multicentrer open-labeled prospective randomized controlled phase 3 study on de novo chronic myeloid leukemia in chronic phase (CML-CP), showed that cumulative achievement rates of MR4.5 (BCR-ABL1 ≤0.0032% on the International Scale [BCR-ABL1IS]) by 18 months were 33.0% (75/227) (95% CI:27.0–39.6%) in the nilotinib (NIL) arm and 30.8% (70/227) (95% CI: 24.9–37.3%) in the dasatinib arm, with no significant difference. After stopping NIL, 76.5% of patients remained in TFR at 12 months later. The results suggest that a higher proportion of patients with CML-CP who achieved sustained MR4.5 on frontline NIL will remain progression free without treatment compared with that in previous TFR trials."

Clinical • Chronic Myeloid Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatology • Leukemia • Oncology • Pancreatic Cancer • Solid Tumor • ABL1 • BCR